Study: Drug Offers Some Relief for Shift-Work Sleep Disorder

Aug. 24, 2005
A recent study offers some potentially promising news for the thousands of Americans who suffer from shift-work sleep disorder.

The study, published in the Aug. 4 issue of the New England Journal of Medicine, found that treatment with 200 milligrams of the drug Modafinil helped reduce the extreme sleepiness common in patients with shift-work sleep disorder and resulted in a "small but significant" improvement in study participants' work performance compared with a placebo.

Of the study participants who took Modafinil, 74 percent saw improvements in their clinical symptoms when evaluated by a physician. Overall, those taking Modafinil fell asleep faster, focused their attention for longer periods of time during night work and avoided accidents or near-accidents while commuting home, according to the study.

The study, led by Charles Czeisler, Ph.D., M.D., chief of the Division of Sleep Medicine at the Brigham and Women's Hospital and a professor of sleep medicine at Harvard Medical School, "represents the first large-scale clinical trial for patients with shift-work sleep disorders," Czeisler told Occupational

"One of the first things we were able to do was document the impact of this debilitating condition on these patients in terms of their ability to stay alert and to perform on the job," Czeisler said.

Workers diagnosed with shift-work sleep disorder chronically suffer from excessive sleepiness during night work and insomnia when trying to sleep during the day. They also "miss family and social activities more frequently and have higher rates of ulcers, sleepiness-related accidents, absenteeism and depression than do night-shift workers without the disorder," according to the study.

About 5 to 10 percent of the nearly 6 million Americans who work at night suffer from shift-work sleep disorder, according to the study.

While the study concludes that Modafinil marketed as "Provigil" by its manufacturer, Frazer, Pa.-based Cephalon Inc. may be a viable treatment for shift-work sleep disorder, Czeisler added that more research is needed to identify other treatment options.

"These are profoundly sleepy patients whose conditions were improved by the treatment but still remained sleepy after treatment," he said.

Czeisler added that medication is just one element in a treatment program for shift-work sleep disorder. Working conditions, lighting and scheduling also can have a big impact on night-shift workers' alertness and performance, he said.

The Food and Drug Administration approved Provigil in January 2004 to treat the excessive sleepiness associated with shift-work sleep disorder and with obstructive sleep apnea/hypopnea syndrome, according to Cephalon.

The most frequently reported side effects of Provigil in clinical trials, according to the company, were headache, nausea, nervousness, stuffy nose, diarrhea, back pain, anxiety, trouble sleeping, dizziness and upset stomach.

Sponsored Recommendations

ISO 45001: Occupational Health and Safety Management Systems (OHSMS)

March 28, 2024
ISO 45001 certification – reduce your organizational risk and promote occupational health and safety (OHS) by working with SGS to achieve certification or migrate to the new standard...

Want to Verify your GHG Emissions Inventory?

March 28, 2024
With the increased focus on climate change, measuring your organization’s carbon footprint is an important first action step. Our Green House Gas (GHG) verification services provide...

Download Free ESG White Paper

March 28, 2024
The Rise and Challenges of ESG – Your Journey to Enhanced Sustainability, Brand and Investor Potential

Free Webinar: Mining & ESG: The Sustainability Mandate

March 28, 2024
Participants in this webinar will understand the business drivers and challenges of ESG and sustainability performance, the 5 steps of the ESG and sustainability cycle, and prioritized...

Voice your opinion!

To join the conversation, and become an exclusive member of EHS Today, create an account today!